Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer

View through CrossRef
<div>Abstract<p>One of the most encouraging developments in oncology has been the success of BRAF inhibitors in <i>BRAF</i>-mutant melanoma. However, in contrast to its striking efficacy in <i>BRAF</i>-mutant melanomas, BRAF inhibitor monotherapy is ineffective in <i>BRAF</i>-mutant colorectal cancer. Although many studies on BRAF inhibitor resistance in colorectal cancer have focused on mechanisms underlying the reactivation of the EGFR/RAS/RAF/MEK/ERK pathway, the current study focuses on identifying novel adaptive signaling mechanisms, a fresh angle on colorectal cancer resistance to BRAF inhibition. We found that treatment with BRAF inhibitors (both current and next-generation BRAF inhibitors) upregulated the Wnt/β-catenin pathway in <i>BRAF</i><sup>V600E</sup>-mutant colorectal cancer cell lines through activating the cytoplasmic tyrosine kinase focal adhesion kinase (FAK). The results showed that FAK activation upon BRAF inhibitor treatment did not require EGFR or ERK1/2 activation, implying that BRAF inhibitor treatment-induced hyperactivation of Wnt signaling is “pathway reactivation”-independent. BRAF inhibition–induced Wnt pathway activation was further validated in preclinical models of <i>BRAF</i><sup>V600E</sup>-mutant colorectal cancer, including cell line xenograft model and a patient-derived xenograft model. Combined inhibition of BRAF/Wnt pathways or BRAF/FAK pathways exerted strong synergistic antitumor effects in cell culture model and mouse xenograft model. Overall, the current study has identified activation of the Wnt/β-catenin pathway as a novel fundamental cause of colon cancer resistance to BRAF inhibition. Our results suggest that although complete vertical pathway blockade is pivotal for effective and durable control of <i>BRAF</i>-mutant colorectal cancer, cotargeting parallel adaptive signaling—the Wnt/β-catenin pathway—is also essential. <i>Mol Cancer Ther; 17(4); 806–13. ©2017 AACR</i>.</p></div>
Title: Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Description:
<div>Abstract<p>One of the most encouraging developments in oncology has been the success of BRAF inhibitors in <i>BRAF</i>-mutant melanoma.
However, in contrast to its striking efficacy in <i>BRAF</i>-mutant melanomas, BRAF inhibitor monotherapy is ineffective in <i>BRAF</i>-mutant colorectal cancer.
Although many studies on BRAF inhibitor resistance in colorectal cancer have focused on mechanisms underlying the reactivation of the EGFR/RAS/RAF/MEK/ERK pathway, the current study focuses on identifying novel adaptive signaling mechanisms, a fresh angle on colorectal cancer resistance to BRAF inhibition.
We found that treatment with BRAF inhibitors (both current and next-generation BRAF inhibitors) upregulated the Wnt/β-catenin pathway in <i>BRAF</i><sup>V600E</sup>-mutant colorectal cancer cell lines through activating the cytoplasmic tyrosine kinase focal adhesion kinase (FAK).
The results showed that FAK activation upon BRAF inhibitor treatment did not require EGFR or ERK1/2 activation, implying that BRAF inhibitor treatment-induced hyperactivation of Wnt signaling is “pathway reactivation”-independent.
BRAF inhibition–induced Wnt pathway activation was further validated in preclinical models of <i>BRAF</i><sup>V600E</sup>-mutant colorectal cancer, including cell line xenograft model and a patient-derived xenograft model.
Combined inhibition of BRAF/Wnt pathways or BRAF/FAK pathways exerted strong synergistic antitumor effects in cell culture model and mouse xenograft model.
Overall, the current study has identified activation of the Wnt/β-catenin pathway as a novel fundamental cause of colon cancer resistance to BRAF inhibition.
Our results suggest that although complete vertical pathway blockade is pivotal for effective and durable control of <i>BRAF</i>-mutant colorectal cancer, cotargeting parallel adaptive signaling—the Wnt/β-catenin pathway—is also essential.
<i>Mol Cancer Ther; 17(4); 806–13.
©2017 AACR</i>.
</p></div>.

Related Results

Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
Data from Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer
<div>Abstract<p>One of the most encouraging developments in oncology has been the success of BRAF inhibitors in <i>BRAF</i>-mutant melanoma. However, in con...
Bortezomib Induces Activation of b-Catenin/TCF Signaling Pathway in Multiple Myeloma
Bortezomib Induces Activation of b-Catenin/TCF Signaling Pathway in Multiple Myeloma
Abstract Abstract 1851 Background: The proteasome inhibitor Bortezomib (Bz) shows significant activity in Multipl...
Abstract 1713: Macrophage-induced bystander effect activates Wnt/β-catenin signaling and induces cellular dedifferentiation
Abstract 1713: Macrophage-induced bystander effect activates Wnt/β-catenin signaling and induces cellular dedifferentiation
Abstract Cancer stem cells (CSCs) in colorectal cancer (CRC) help maintain tumor heterogeneity, promote tumor growth, invasion, and metastasis, and produce resistanc...
Abstract 5177: E7386 : First-in-class orally active CBP/beta-catenin modulator as an anticancer agent
Abstract 5177: E7386 : First-in-class orally active CBP/beta-catenin modulator as an anticancer agent
Abstract Carcinogenesis is often accelerated by the aberrant activation of components molecules of Wnt signaling pathway, especially, APC and beta-catenin are freque...
Abstract 1584: Wnt/beta-catenin and Foxa2 axis activates AR signaling in castration resistant prostate cancer
Abstract 1584: Wnt/beta-catenin and Foxa2 axis activates AR signaling in castration resistant prostate cancer
Abstract Background: Prostate cancer (PCa) is the leading cancer among men in the world. Androgen deprivation therapy is a common treatment to cease prostate growth....
Wnt/β-catenin/HNF4α feedback loop facilitates colorectal tumorigenesis and malignancy
Wnt/β-catenin/HNF4α feedback loop facilitates colorectal tumorigenesis and malignancy
Abstract Background: The Wnt/β-catenin signaling pathway is a central regulator of colorectal cancer (CRC) development, yet its downstream targets and mechanistic contribut...
Ethacrynic Acid Can Inhibit Wnt/β-Catenin Signaling and Induce Apoptosis in Chronic Lymphocytic Leukemia Cells.
Ethacrynic Acid Can Inhibit Wnt/β-Catenin Signaling and Induce Apoptosis in Chronic Lymphocytic Leukemia Cells.
Abstract Chronic lymphocytic leukemia (CLL) is caused by an abnormal balance in signals for survival and cell death. Recently, CLL cells are shown to have an activat...
Abstract 630: The role of AKT pathway in β-catenin mutated hepatocellular carcinoma
Abstract 630: The role of AKT pathway in β-catenin mutated hepatocellular carcinoma
Abstract The Wnt/β-catenin and PI3K/AKT pathways are pivotal contributors to the development of the malignant phenotype in cancer. The activated Wnt/β-catenin pathwa...

Back to Top